Menu
Search
|

Menu

Close
X

Lexicon Pharmaceuticals Inc LXRX.OQ (NASDAQ Stock Exchange Global Select Market)

13.58 USD
+0.51 (+3.90%)
As of Jun 22
chart
Previous Close 13.07
Open 13.26
Volume 565,405
3m Avg Volume 221,838
Today’s High 13.77
Today’s Low 13.11
52 Week High 17.96
52 Week Low 7.68
Shares Outstanding (mil) 105.58
Market Capitalization (mil) 1,239.53
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
25
FY17
90
FY16
83
FY15
130
EPS (USD)
FY18
-0.398
FY17
-1.265
FY16
-1.362
FY15
-0.133
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
15.28
5.71
Price to Book (MRQ)
vs sector
11.66
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
94.57
16.46
LT Debt to Equity (MRQ)
vs sector
80.31
12.19
Return on Investment (TTM)
vs sector
-42.10
14.38
Return on Equity (TTM)
vs sector
-85.52
16.08

EXECUTIVE LEADERSHIP

Raymond Debbane
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Lonnel Coats
President, Chief Executive Officer, Director, Since 2014
Salary: $597,568.00
Bonus: $444,675.00
Jeffrey Wade
Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs, Since 2015
Salary: $416,783.00
Bonus: $182,393.00
Pablo Lapuerta
Executive Vice President, Chief Medical Officer, Since 2015
Salary: $385,949.00
Bonus: $144,400.00
Alan Main
Executive Vice President - CMC and Supply Operations, Since 2015
Salary: $369,245.00
Bonus: $138,030.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8800 Technology Forest Pl
THE WOODLANDS   TX   77381-1160

Phone: +1281.8633000

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

SPONSORED STORIES